Home/Filings/4/0001671311-25-000005
4//SEC Filing

Jarrett Jennifer 4

Accession 0001671311-25-000005

CIK 0001724521other

Filed

Nov 11, 7:00 PM ET

Accepted

Nov 12, 4:04 PM ET

Size

8.8 KB

Accession

0001671311-25-000005

Insider Transaction Report

Form 4
Period: 2025-11-07
Jarrett Jennifer
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-07$1.23/sh+50,291$61,737264,523 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-07$1.23/sh50,291$61,73780,583 total
    Exercise: $1.23Exp: 2027-03-14Common Stock (50,291 underlying)
  • Sale

    Common Stock

    2025-11-07$18.97/sh50,291$954,066214,232 total
Footnotes (3)
  • [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.59 to $19.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The option is fully vested and currently exercisable.

Issuer

Arcus Biosciences, Inc.

CIK 0001724521

Entity typeother

Related Parties

1
  • filerCIK 0001671311

Filing Metadata

Form type
4
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:04 PM ET
Size
8.8 KB